The Different Association between Metformin and Sulfonylurea Derivatives and the Risk of Cancer May be Confounded by Body Mass Index
Journal Title: Journal of Diabetes and Obesity - Year 2016, Vol 3, Issue 2
Abstract
Aim: Several studies in large databases suggest that in comparison to glucose-lowering sulfonylurea derivatives, metformin is associated with a reduced risk of cancer in patients with diabetes. As many databases miss relevant confounder data, our objective was to investigate whether the determinants age, body mass index (BMI), alcohol consumption, and renal function were associated with dispensing of either metformin or sulfonylurea derivatives as first drug therapy for type 2 diabetes mellitus while taking into account calendar time. Methods: We identified 639 incident metformin users and 934 incident sulfonylurea derivatives users in the Rotterdam Study, a prospective population-based cohort study. Associations were studied using logistic regression analyses. Results: After adjustment for all other determinants, starters with metformin had a statistically significantly higher BMI than starters with sulfonylurea derivatives (OR 1.19, 95% CI 1.04 – 1.37 for starters < July 1st 2000; OR 1.23, 95% CI 1.04 – 1.45 for starters ≥ July 1st 2000). Age, renal function, and alcohol consumption were not statistically significantly associated with the probability of dispensing metformin versus sulfonylurea derivative therapy as first drug therapy for type 2 diabetes mellitus. Conclusion: BMI is associated with a higher probability of dispensing of metformin as first drug therapy for type 2 diabetes mellitus in comparison to sulfonylurea derivatives. BMI is associated with the risk of cancer as well as the risk of type 2 diabetes mellitus. Therefore, in studies analyzing the association between the use of metformin or sulfonylurea derivatives and the risk of cancer, BMI should be considered as an essential co-variable.
Authors and Affiliations
Rikje Ruiter
Keywords
Related Articles
- EP ID EP417846
- DOI 10.15436/2376-0494.16.1007
- Views 75
- Downloads 0
Effect of Haematogenous oxidation therapy with Ultraviolet-C irridation in an alloxan-induced diabetes and a Poloxamer 407-induced Hyperlipidemia in rabbits
Background Recently diabetes and hyperlipidemia HL considered a major source of mortality Chemical treatments could minimize the symptoms but still the disease exists Previously Ultraviolet was usedfor treatment...
Diabetes Risk Factors for Chronic Kidney Patients
Diabetes Mellitus DM Chronic Kidney Disease CKD and Coronary Heart Disease CHD are in practice a complex medical status which are closely associated and generally coexist This article focuses the diabetes risk f...
Possibility of Diabetes Prevention by High-amylose Rice and Super Hard Rice
Diabetes is one of the most devastating diseases in the world Its prevention is very important in addition to the development of the curing technology We started the cooperative research on low Glycemic Index GI rice...
The Relationship between Obesity and Diabetes
Diabetes mellitus (DM) is a lifelong condition that can transform carbohydrate, protein and fat metabolism. The cause of which is the lack of the hormone insulin as a result of either the ongoing or striking failure of t...
Potential New Pharmacological Approaches in Obese Women with Polycystic Ovary Syndrome
Obesity is frequently present in women with polycystic ovary syndrome PCOS It aggravates the adverse features of the syndrome and increases the metabolic risk in this population Weight management by life style interv...